Loading organizations...

§ Private Profile · San Francisco, CA, USA
The AI data analyst for biology labs
Novaflow has raised $500K across 1 funding round.
Key people at Novaflow.
Novaflow was founded in 2025 by Amulya Balakrishnan (Founder/ CTO) and Aman Agarwal (Founder/CEO).
Novaflow has raised $500K in total across 1 funding round.
Novaflow is the AI data analyst for biology labs.
--
Bioinformatics data analysis is a time-consuming and expensive process for scientists. With Novaflow, life scientists can upload experimental data, ask questions in plain English, and get instant, publication-ready plots, giving them results in minutes instead of months.
Researchers at leading institutions like UCSF, Mount Sinai, UC Berkeley, and Harvard are already using Novaflow in their labs.
Novaflow has raised $500K across 1 funding round. Most recently, it raised $500K Seed in July 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2025 | $500K Seed | — | LiveOak Venture Partners, Y Combinator | Announced |
Key people at Novaflow.
Novaflow was founded in 2025 by Amulya Balakrishnan (Founder/ CTO) and Aman Agarwal (Founder/CEO).
Novaflow has raised $500K in total across 1 funding round.
Novaflow's investors include LiveOak Venture Partners, Y Combinator.
Novaflow is an AI-powered bioinformatics platform designed to automate complex data analysis workflows for life science researchers and biology labs. It transforms raw experimental data into publication-ready, interactive visualizations and reproducible results within minutes, eliminating the need for coding or manual pipeline setup. By leveraging large language models (LLMs), Novaflow enables scientists to use natural language prompts to initiate analyses, significantly accelerating the research process and reducing costs associated with traditional bioinformatics workflows. The platform primarily serves researchers, labs, and biotech teams, helping them focus more on scientific discovery rather than data wrangling[1][2][3].
Novaflow was founded by Aman Agarwal, a computational biologist, and Amulya Balakrishnan, a former software engineer at Zoom. Aman experienced firsthand the challenges faced by life scientists who struggled with slow, expensive, and talent-constrained bioinformatics analysis, often spending over $100,000 annually on data processing with long delays. Recognizing the potential of LLMs to automate and streamline this process, Aman and Amulya teamed up to build Novaflow, aiming to put data analysis back into the hands of researchers. The company gained early traction by demonstrating how it could reduce analysis time from months to minutes, making complex workflows accessible without specialized bioinformatics expertise[2][3][6].
Novaflow rides the wave of AI-driven automation and democratization of complex scientific data analysis. The timing is critical as life sciences generate exponentially growing datasets, but analysis remains a bottleneck due to high costs, specialized skill requirements, and slow turnaround times. By integrating LLMs and automating bioinformatics pipelines, Novaflow addresses these market forces, enabling faster, more reproducible research. This innovation not only accelerates scientific discovery but also influences the broader ecosystem by lowering barriers for smaller labs and biotech startups to perform advanced analyses without heavy investment in bioinformatics talent[1][2][3][7].
Novaflow is positioned to become a key enabler in the life sciences research community by continuing to expand its AI capabilities and workflow coverage. Future trends shaping its journey include increasing adoption of AI in scientific workflows, growing demand for reproducibility and transparency in research, and the ongoing explosion of biological data. As Novaflow scales, it may evolve into a platform that integrates with broader lab management and research ecosystems, further embedding AI-driven analysis into everyday scientific practice. Its influence could extend beyond biology labs to impact drug discovery, personalized medicine, and biotech innovation, reinforcing its mission to accelerate scientific progress by putting data analysis directly into researchers’ hands[1][2][3][7].